RecruitingPhase 2NCT07215312
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
Sponsor
Eli Lilly and Company
Enrollment
100 participants
Start Date
Oct 13, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Have type 2 diabetes
- Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
- Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
- Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion Criteria1
- Have type 1 diabetes
Interventions
DRUGLY3938577
Administered SC
DRUGDegludec
Administered SC
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07215312
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418115 locations
Project Dulce for Arab Americans With Type 2 Diabetes
NCT055805362 locations
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
NCT038787061 location
Food Insecurity Reduction & Strategy Team
NCT063293751 location